A study from CARE fertility reports tripled rates of embryo implantation following 24sure test
BlueGnome’s single cell aneuploidy screening platform, 24sure, used to screen embryos for chromosome abnormalities, has increased embryo implantation three-fold, states a paper published in the journal Fertilisation in Vitro (1).
The paper details a study of 150 cases of IVF using 24sure carried out at CARE Fertility in Nottingham and Manchester. Oliver, was the world’s first baby, born in 2009, following 24sure testing. Oliver’s mother had suffered 13 failed attempts at IVF until her embryos were screened for abnormal chromosomes (aneuploidy).
The study followed 134 couples presenting for 150 cycles of 24sure with a median age of 41 in the female and a history of miscarriage or failed IVF. The procedure involved a laser assisted removal of the polar body from the fertilised egg, then checking the chromosome complement using 24sure. The rapid screening process allowed fresh transfer of viable embryos, with no need to freeze whilst results were obtained.
Professor Simon Fishel, lead author and Managing Director of CARE Fertility said: “We know that chromosome abnormality is a major cause of miscarriage and IVF failure. Our team at CARE have studied 150 cases, the largest study undertaken world-wide and concluded that using this technique dramatically increases the chance of implantation. All couples undergoing IVF could benefit from this test which can reliably detect faulty chromosomes prior to implantation.”
Simon Fishel continued, “24sure is a not only a triumph of UK ingenuity but also a real insight into the viability of an embryo. CARE’s scientists examine thousands of embryos every year, deciding which embryo to replace is critical. 24sure can give us reliable information to help us make that decision”.
Since the birth of baby Oliver, the collaboration between CARE Fertility Group and Cambridge laboratory BlueGnome has developed the chromosome test which is now being used in over 60 laboratories worldwide.
Nick Haan (CEO BlueGnome), “The publication of this paper provides further evidence of the benefits of including 24sure in the management of some of the more challenging IVF cases. Our expectation is that the same technique can now be applied more widely in order to improve the overall outcome of IVF”.
A recent published study by the European Society of Human Reproduction (ESHRE) of 42 cases has also confirmed the reliability of 24sure testing.
(1) Assessment of 19,803 Paired Chromosomes and Clinical Outcome from First 150 Cycles using Array CGH of the First Polar Body for Embryo Selection and Transfer.
Fishel et al. J Fertiliz In Vitro 2011, 1:1
About BlueGnome
BlueGnome (www.cytochip.com) is a specialist developer of microarray based solutions for the screening of chromosomal abnormalities in cytogenetics and IVF.
BlueGnome microarrays are for research use only.
For further information please contact:
BlueGnome Ltd, Mill Court, Great Shelford, Cambridge, CB22 5LD, UK.
T: +44 1223 844441 F: +44 1223 844445 E: info@24suretest.com
About CARE
CARE was founded in 1997 to provide fertility services to private and NHS patients. Since then we have helped thousands of couples and we are now the UK's largest independent provider of assisted conception cycles, around 3,500 annually.
For further information please contact:
Wanda Georgiades, CARE Fertility, Nottingham on 0115 8528163 or email wanda@carefertility.com
Nottingham 26th January 2012